guest ::
| Home > Publications Database > PET/CT imaging of differentiated and medullary thyroid carcinoma using the novel SSTR-targeting peptide [18F]SiTATE - first clinical experiences. > print |
| Home > Publications Database > PET/CT imaging of differentiated and medullary thyroid carcinoma using the novel SSTR-targeting peptide [18F]SiTATE - first clinical experiences. > print |
| 001 | 276155 | ||
| 005 | 20250204165927.0 | ||
| 024 | 7 | _ | |a 10.1007/s00259-024-06944-y |2 doi |
| 024 | 7 | _ | |a pmid:39404789 |2 pmid |
| 024 | 7 | _ | |a 1619-7070 |2 ISSN |
| 024 | 7 | _ | |a 1619-7089 |2 ISSN |
| 037 | _ | _ | |a DZNE-2025-00227 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Kunte, Sophie C |b 0 |
| 245 | _ | _ | |a PET/CT imaging of differentiated and medullary thyroid carcinoma using the novel SSTR-targeting peptide [18F]SiTATE - first clinical experiences. |
| 260 | _ | _ | |a Heidelberg [u.a.] |c 2025 |b Springer-Verl. |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1738669147_28058 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a The novel 18F-labeled somatostatin receptor (SSTR)-directed radiotracer [18F]SiTATE demonstrated promising results for the imaging of various SSTR-expressing tumor types. Although thyroid carcinomas (TC) express SSTR, data on [18F]SiTATE PET/CT imaging in TC are lacking. This study explores the use of [18F]SiTATE PET/CT in a patient cohort with histologically proven TC.As part of a prospective observational study at a single tertiary cancer center, 21 patients with TC (10 medullary (MTC) and 11 differentiated (DTC)) who underwent at least one [18F]SiTATE PET/CT were included (37 scans in total). Mean SUVmax and SUVmean of tumoral lesions, mean total-tumor-volume (TTV), and whole-body (WB)-SUVmax and WB-SUVmean on PET with their standard deviations (SDs) were determined. PET parameters were correlated to clinical parameters including tumor marker levels (thyroglobulin for DTC, calcitonin for MTC).89 lesions were included in the analysis. Metastases were localized in the bone, lymph nodes, lung, soft tissue, and thyroid bed. Osseous (31 lesions; SUVmax 8.6 ± 8.0; SUVmean 5.8 ± 5.4) and nodal (37 lesions; SUVmax 8.7 ± 7.8; SUVmean 5.7 ± 5.4) metastases showed the highest uptake. The MTC disease burden on PET significantly correlated with the calcitonin tumor marker level (e.g., TTV: r = 0.771, r2 = 0.594, p = 0.002). For DTC, no such correlation was present.Our data demonstrate high feasibility of [18F]SiTATE PET/CT in a small cohort of patients with MTC and DTC. The use of [18F]SiTATE may overcome logistical disadvantages of 68Ga-based tracers and facilitate SSTR-targeted PET/CT imaging of thyroid carcinoma. |
| 536 | _ | _ | |a 352 - Disease Mechanisms (POF4-352) |0 G:(DE-HGF)POF4-352 |c POF4-352 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de |
| 650 | _ | 7 | |a (4–6): Medullary thyroid carcinoma (MTC) |2 Other |
| 650 | _ | 7 | |a Differentiated thyroid carcinoma (DTC) |2 Other |
| 650 | _ | 7 | |a Follicular thyroid carcinoma (FTC) |2 Other |
| 650 | _ | 7 | |a Papillary thyroid carcinoma (PTC) |2 Other |
| 650 | _ | 7 | |a Serum tumor marker |2 Other |
| 650 | _ | 7 | |a Somatostatin receptor (SSTR) |2 Other |
| 650 | _ | 7 | |a Receptors, Somatostatin |2 NLM Chemicals |
| 650 | _ | 7 | |a Fluorine Radioisotopes |2 NLM Chemicals |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Thyroid Neoplasms: diagnostic imaging |2 MeSH |
| 650 | _ | 2 | |a Thyroid Neoplasms: metabolism |2 MeSH |
| 650 | _ | 2 | |a Male |2 MeSH |
| 650 | _ | 2 | |a Female |2 MeSH |
| 650 | _ | 2 | |a Positron Emission Tomography Computed Tomography |2 MeSH |
| 650 | _ | 2 | |a Middle Aged |2 MeSH |
| 650 | _ | 2 | |a Carcinoma, Neuroendocrine: diagnostic imaging |2 MeSH |
| 650 | _ | 2 | |a Receptors, Somatostatin: metabolism |2 MeSH |
| 650 | _ | 2 | |a Adult |2 MeSH |
| 650 | _ | 2 | |a Aged |2 MeSH |
| 650 | _ | 2 | |a Fluorine Radioisotopes |2 MeSH |
| 700 | 1 | _ | |a Wenter, Vera |b 1 |
| 700 | 1 | _ | |a Toms, Johannes |b 2 |
| 700 | 1 | _ | |a Lindner, Simon |b 3 |
| 700 | 1 | _ | |a Unterrainer, Marcus |b 4 |
| 700 | 1 | _ | |a Eilsberger, Friederike |b 5 |
| 700 | 1 | _ | |a Jurkschat, Klaus |b 6 |
| 700 | 1 | _ | |a Wängler, Carmen |b 7 |
| 700 | 1 | _ | |a Wängler, Björn |b 8 |
| 700 | 1 | _ | |a Schirrmacher, Ralf |b 9 |
| 700 | 1 | _ | |a Tiling, Maximilian W |b 10 |
| 700 | 1 | _ | |a Sheikh, Gabriel T |b 11 |
| 700 | 1 | _ | |a Mehrens, Dirk |b 12 |
| 700 | 1 | _ | |a Brendel, Matthias |0 P:(DE-2719)9001539 |b 13 |u dzne |
| 700 | 1 | _ | |a Rübenthaler, Johannes |b 14 |
| 700 | 1 | _ | |a Auernhammer, Christoph J |b 15 |
| 700 | 1 | _ | |a Spitzweg, Christine |b 16 |
| 700 | 1 | _ | |a Unterrainer, Lena M |b 17 |
| 700 | 1 | _ | |a Holzgreve, Adrien |0 0000-0002-9566-8438 |b 18 |
| 773 | _ | _ | |a 10.1007/s00259-024-06944-y |g Vol. 52, no. 3, p. 900 - 912 |0 PERI:(DE-600)2098375-X |n 3 |p 900 - 912 |t European journal of nuclear medicine and molecular imaging |v 52 |y 2025 |x 1619-7070 |
| 856 | 4 | _ | |y OpenAccess |u https://pub.dzne.de/record/276155/files/DZNE-2025-00227.pdf |
| 856 | 4 | _ | |y OpenAccess |x pdfa |u https://pub.dzne.de/record/276155/files/DZNE-2025-00227.pdf?subformat=pdfa |
| 909 | C | O | |o oai:pub.dzne.de:276155 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 13 |6 P:(DE-2719)9001539 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-352 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Disease Mechanisms |x 0 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-05 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2024-12-05 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2024-12-05 |
| 915 | _ | _ | |a Creative Commons Attribution CC BY 4.0 |0 LIC:(DE-HGF)CCBY4 |2 HGFVOC |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2024-12-05 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b EUR J NUCL MED MOL I : 2022 |d 2024-12-05 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2024-12-05 |
| 915 | _ | _ | |a DEAL Springer |0 StatID:(DE-HGF)3002 |2 StatID |d 2024-12-05 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-05 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2024-12-05 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b EUR J NUCL MED MOL I : 2022 |d 2024-12-05 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-05 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2024-12-05 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-05 |
| 920 | 1 | _ | |0 I:(DE-2719)1110007 |k AG Haass |l Molecular Neurodegeneration |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-2719)1110007 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|